KBC Group’s Adaptimmune Therapeutics ADAP Stock Holding History

KBC Group’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-45,900	Closed	-$237K	–	1282
2021 Q3	$237K	Sell	45,900 -5,900	-11%	-$26.5K	﹤0.01%	1034
2021 Q2	$220K	Buy	51,800 +38,000	+275%	+$184K	﹤0.01%	1159
2021 Q1	$74K	Buy	13,800 +6,000	+77%	+$34.3K	﹤0.01%	1262
2020 Q4	$231K	Hold	7,800	–	–	﹤0.01%	1247
2020 Q3	$62K	Sell	7,800 -4,000	-34%	-$35K	﹤0.01%	1200
2020 Q2	$118K	Buy	11,800 +5,900	+100%	+$37.1K	﹤0.01%	1201
2020 Q1	$16K	Hold	5,900	–	–	﹤0.01%	1260
2019 Q4	$7K	Buy	5,900 +5,730	+3,371%	+$6.11K	﹤0.01%	1481
2019 Q3	$0	Sell	170 -1,730	-91%	-$4.04K	﹤0.01%	1480
2019 Q2	$8K	Hold	1,900	–	–	﹤0.01%	1441
2019 Q1	$8K	Buy	1,900 +950	+100%	+$4.42K	﹤0.01%	1399
2018 Q4	$5K	Hold	950	–	–	﹤0.01%	1302
2018 Q3	$13K	Hold	950	–	–	﹤0.01%	1379
2018 Q2	$11K	Hold	950	–	–	﹤0.01%	1279
2018 Q1	$11K	Hold	950	–	–	﹤0.01%	1260
2017 Q4	$6K	Buy	+950	New	+$7.34K	﹤0.01%	1254

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KBC Group's ADAP Position: Q4 2021 in Review

KBC Group sold out of Adaptimmune Therapeutics (ADAP) in Q4 2021, closing a stake of 45,900 shares — an estimated $237K sold.

KBC Group first reported a position in ADAP in Q4 2017 and held it in 16 quarters. The position peaked at $237K in Q3 2021. 85 funds tracked by Wall St. Rank hold ADAP as of Q4 2021.

KBC Group reported no remaining Adaptimmune Therapeutics position as of Q4 2021 after selling out during the quarter.
KBC Group sold 45,900 Adaptimmune Therapeutics shares in Q4 2021, an estimated $237K.
KBC Group first reported a position in Adaptimmune Therapeutics in Q4 2017 and held it in 16 quarters.
KBC Group's Adaptimmune Therapeutics position peaked at $237K in Q3 2021.
85 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2021.

Based on KBC Group's 13F filing for Q4 2021, filed 3 Feb 2022.